Biontech Cell&gene Therapies Gmbh competitive analysis

Explore Biontech Cell&gene Therapies Gmbh's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Aug 20, 2026
Patent NumberPublication DateTitleTotal Oppositions
Jul 9, 2025Claudin-18.2-Specific Immunoreceptors And T Cell Epitopes1
Jul 26, 2023Enhancing The Effect Of Car-Engineered T Cells By Means Of Nucleic Acid Vaccination1
Feb 16, 2022Claudin-6-Specific Immunoreceptors And T Cell Epitopes2

Latest PTAB cases involving Biontech Cell&gene Therapies Gmbh

Discover the latest PTAB cases involving Biontech Cell&gene Therapies Gmbh, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Biontech Cell&gene Therapies Gmbh with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Aug 20, 2026
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
BIONTECH CELL&GENE THERAPIES - 4 - -
DR H ULRICH DORRIES26 - - -
SCHIWECK WEINZIERL KOCH3 - - -
SCHIWECK WEINZIERL KOCH PATENTANWALTE PARTNERSCHAFT MBB23 - - -